Stocksigma LogoStocksigma Logo

IOL Chemicals Reports Strong Q2 FY27 Financial Results and Growth Initiatives

IOL Chemicals reported standalone revenue of ₹795.0 Cr for Q2 FY27, up 40.1% YoY (5.1% QoQ), while EBITDA jumped 79.6% YoY to ₹114.9 Cr with margins

IOL Chemicals Reports Strong Q2 FY27 Financial Results and Growth Initiatives

IOL Chemicals & Pharmaceuticals Ltd · Investor Presentation · 02 Nov 2026, 1:21 pm

IOL Chemicals Reports Strong Q2 FY27 Financial Results and Growth Initiatives IOL Chemicals reported standalone revenue of ₹795.0 Cr for Q2 FY27, up 40.1% YoY (5.1% QoQ), while EBITDA jumped 79.6% YoY to ₹114.9 Cr with margins expanding to 14.4%. PAT surged 116.8% YoY to ₹65.0 Cr. For H1 FY27, revenue reached ₹1551.3 Cr (+38.6% YoY) and PAT stood at ₹129.5 Cr (+102.5% YoY). The company announced a ₹495 Cr capex program across three strategic projects: expanding Ibuprofen capacity by 6,000 MTPA (₹350 Cr), entering CDMO formulations (₹110 Cr), and a specialty chemicals tolling unit (₹35 Cr).

Original exchange filing (PDF)

More announcements from IOL Chemicals & Pharmaceuticals Ltd

All IOL Chemicals & Pharmaceuticals Ltd announcements